Tag: oncology
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
-
Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the CBI Basket and Umbrella Trials for Oncology Conference in Philadelphia, Pennsylvania on Oct 17-18, 2018.
-
Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto, Japan.
-
Andarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29 in Andover, NH.
-
Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge , MA June 19-20.
-
A Billion Dollar Drug Using a Virtual Business Model
Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient
-
Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, IL June 2-6 2017.
-
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high SSTR expression levels…
-
Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling
ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules.
-
Andarix Selected to Present at Prominent Drug Development Conferences
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…